University of Pittsburgh
Antiestrogenic DTACs inhibit estrogen receptor alpha-mediated transcription
Published in Healthcare Mergers, Acquisitions and Ventures Week, December 4th, 2004
According to a study from the United States, "A novel class of pure antiestrogens, 1,1-dichloro-2,2,3-triarylcyclopropanes (DTACs), lack estrogenic activity in a mouse uterotrophic assay and inhibit the growth of estrogen-sensitive MCF-7 breast cancer cells (Day et al., 1991).
"Reporter assays were used to evaluate the effects of the DTACs on estrogen receptor alpha(ERalpha)-mediated transcription from either classic estrogen-response elements (EREs) or nonclassic AP-1 elements."
"Among the DTACs tested," reported P. Cheng and coworkers, "only the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- Aastrom Biosciences, Inc.
Regenerative medicines company raises $10M in equity financing - Abiomed, Inc.
Cardiac device maker reports 95% revenue growth - Able Laboratories, Inc.
Pharmaceutical firm reports 30.8% increase in sales - Accelr8 Technology Corporation
Biotech company reports loss of $0.17 per share - Accredo Health, Incorporated
Biopharmaceutical firm reaffirms fiscal 2005 estimates - Adolor Corporation
Biopharmaceutical company reports loss of $0.22 per share - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
